Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

4SC’s Experimental Hodgkin’s Lymphoma Drug Awarded Orphan Status

Don't Miss Out —
Follow us on:

Sept. 26 (Bloomberg) -- 4SC AG said U.S. regulators granted orphan drug status to the experimental Hodgkin’s Lymhoma drug Resminostat.

Link to Statement:{NSN LS47B93PWT1D <GO>}

Link to Company News:{VSC GR <Equity> CN <GO>}

To contact the editor responsible for this story: Angela Cullen at acullen8@bloomberg.net

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.